Clinical Trial ECOG 2810
- Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy
- Principal Investigator
- Benedito Carneiro
- Status: CLOSED
- Study Type: Therapeutic, Treatment
- Protocol No:.ECOG 2810
- The purpose of this study is to see if pazopanib can reduce the risk of renal cell carcinoma recurring (kidney cancer that comes back) after surgical removal of the cancer.
- In cases where metastatic renal cell carcinoma (kidney cancer that spread) was surgically removed (metastatectomy) the follow up plan is observation and then treatment if there is any sign of the cancer returning. The medical community is always looking for ways to improve the standard of care for cancer. Pazopanib (the study drug) is approved by the Food and Drug Administration (FDA) for metastatic renal cell carcinoma. It has not been tested as a follow-up treatment after metastatectomy to see if it would help reduce the risk of the cancer returning in the future. In this study its use is considered experimental.
Some of the eligibility criteria include:
- Participants must be 18 years of age or older.
- Participants must have had a nephrectomy or partial nephrectomy(surgery to remove all or part of the kidney) for renal cell carcinoma.
- Participants must have metastatic renal cell carcinoma and have undergone surgical resection (removal of the cancer) in one or more areas.
- Description of Treatment
- Participants will be randomized (like the flip of a coin) by computer to one of two groups. Both groups will be taking 4 tablets by mouth every day for 52 weeks. Group 1 will receive pazopanib. Group 2 will receive a placebo (a pill that looks the same as the study drug but does not have any medicine).
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Benedito Carneiro
- A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination with Docetaxel plus Prednisone in Metastatic Castration Resistant Prostate Cancer
- A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
last updated: 24-Mar-17 10:58 AM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.